EIM
CYTK icon

Essex Investment Management’s Cytokinetics CYTK Stock Holding History

Essex Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-84,690
Closed -$610K – 403
2018
Q1 		$610K Sell
84,690
-23,038
-21% -$198K 0.08% 254
2017
Q4 		$878K Buy
107,728
+28,970
+37% +$329K 0.12% 224
2017
Q3 		$1.14M Buy
78,758
+32,229
+69% +$440K 0.16% 196
2017
Q2 		$563K Buy
46,529
+17,510
+60% +$243K 0.08% 249
2017
Q1 		$373K Buy
+29,019
New +$339K 0.06% 286

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

Essex Investment Management's CYTK Position: Q2 2018 in Review

Essex Investment Management sold out of Cytokinetics (CYTK) in Q2 2018, closing a stake of 84,690 shares — an estimated $610K sold.

Essex Investment Management first reported a position in CYTK in Q1 2017 and held it in 5 quarters. The position peaked at $1.14M in Q3 2017. 126 funds tracked by Wall St. Rank hold CYTK as of Q2 2018.

  • Essex Investment Management reported no remaining Cytokinetics position as of Q2 2018 after selling out during the quarter.
  • Essex Investment Management sold 84,690 Cytokinetics shares in Q2 2018, an estimated $610K.
  • Essex Investment Management first reported a position in Cytokinetics in Q1 2017 and held it in 5 quarters.
  • Essex Investment Management's Cytokinetics position peaked at $1.14M in Q3 2017.
  • 126 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2018.

Based on Essex Investment Management's 13F filing for Q2 2018, filed 17 Jul 2018.